Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17053147 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Dorrello NV, et al. (2006) S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467-71 17053147
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum no effect upon treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum no effect upon treatment-induced increase
U0126 serum inhibit treatment-induced increase

T412-p - p70S6K (human) ▲
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase

S67-p - PDCD4 (human) ▲
Orthologous residues
PDCD4 (human): S67‑p, PDCD4 (mouse): S67‑p, PDCD4 (rat): S67‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  293T (epithelial), T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE p70S6K (human) transfection of constitutively active enzyme, modification site within consensus motif, transfection of inactive enzyme, phospho-antibody, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation, protein degradation
 Effect of modification (process):  cell cycle regulation, cell growth, altered, translation, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces pull-down assay, co-immunoprecipitation

S71-p - PDCD4 (human) ▲
Orthologous residues
PDCD4 (human): S71‑p, PDCD4 (mouse): S71‑p, PDCD4 (rat): S71‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  293T (epithelial), T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  molecular association, regulation, protein degradation
 Effect of modification (process):  cell cycle regulation, cell growth, altered, translation, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces pull-down assay, co-immunoprecipitation

S76-p - PDCD4 (human) ▲
Orthologous residues
PDCD4 (human): S76‑p, PDCD4 (mouse): S76‑p, PDCD4 (rat): S76‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  293T (epithelial), T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  molecular association, regulation, protein degradation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BTRC (human) Induces pull-down assay, co-immunoprecipitation

S235-p - S6 (human) ▲
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase

S236-p - S6 (human) ▲
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, glioblastoma, glioblastoma multiforme, glioma
 Relevant cell lines - cell types - tissues:  T98G (glial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
rapamycin serum inhibit treatment-induced increase
SB203580 serum no effect upon treatment-induced increase
LY294002 serum inhibit treatment-induced increase
U0126 serum no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.